Customize your experience
You decide what information you want to see on your Sanofi Campus
More about science
Choose a therapeutic area to find related scientific content
Cardiovascular
Diabetes
Atopic Dermatitis
Asthma
Nasal Polyps
Rare Diseases
Vaccines
Multiple Sclerosis
Prurigo Nodularis
Latest trends
Explore the most popular scientific articles and videos among Campus Sanofi users
2019 ESC Guidelines for Acute Pulmonary Embolism
A Meningitis Survivor: Daniel Advocates for Prevention
A promising biomarker in MS: Neurofilament light chain
ASH 2019 Guidelines for Surgical Prophylaxis
ASMD PhenoTypes
About Type 2 Inflammation - Atopic Dermatitis
About Type 2 Inflammation - Nasal Polyps
About Type 2 Inflammation – Asthma
Achievement of lipid modification goals with Statins & Ezetimibe
Acute Medical Illness: Advanced Age Alone Predicts Venous Thromboembolism Similar to Existing Risk Assessment Models
Adherence and persistence analysis in patients treated with DAPT
Anticoagulation in COVID-19 Expert consensus from Mayo Clinic
Events
Stay up to date and register for the latest events and view webinar recordings
What is Epilepsy
Insulin@100 Live Webinar. Discovery. Transformation. Legacy.
Roadmap to antimicrobial prescribing
Diabetes Guidelines in Ramadan
Dyslipidemia Webinars: Optimizing Dyslipidemia management
Introduction to Gaucher Disease by Prof. Moeenaldeen D. Alsayed
Nutrition and Insulin management in Ramadan
Soliqua and Unmet Needs Webinar Summary
Type 2 Diabetes Cost Effective Management
Do not Keep it masked! Prof. Fatih Ezgü
Dyslipidemia Webisodes: Mortality data with Prof. Tunon
Pertussis & Polio-based Vaccines; Throughout LIFE Webinar Session
Support for your patients
Discover the selection of support materials for patients from different therapeutic areas
Hyperglycemia
Hypoglycemia
About Diabetes
SCORAD
Treat Early
Dose adjustment of insulins and other medications during Ramadan
ACS EuroPath Project
Identify Your Patient
ESC/EAS Guidelines
ADA Diabetes Treatment Guidelines
ADA Diabetes Diagnosis Guidelines
Sanofi Pioneering possibilities in diabetes management
Sanofi in News
Discover headline news on how Sanofi is engaged with the medical community
Sanofi signs multi-pronged partnership with Dasman Diabetes Institute to intensify diabetes prevention in Kuwait
Saudi Health Council, Sanofi partner to boost diabetes studies and research in the kingdom
Our Products
Clexane®
Enoxaparin Sodium is a low molecular weight heparin (LMWH) that is administered subcutaneously and used as antithrombotic agent.
Praluent®
Alirocumab is a fully human IgG1 monoclonal antibody. It’s a PCSK9 inhibitor that is administered subcutaneously.
Plavix®
Clopidogrel is an inhibitor of platelet aggregation administered orally and indicated for Secondary prevention of atherothrombotic events.
Zympass®
Combination of Rosuvastatin Calcium & Ezetimibe used as adjunct to diet for treatment of Primary Hypercholesterolemia or Homozygous Familial Hypercholesterolemia.
Soliqua®
Combination of Insulin Glargine (a basal insulin analog) & Lixisenatide (a GLP-1 receptor agonist) administered subcutaneously.
Dupixent®
Is a fully human monoclonal antibody with multiple indications in different therapeutic areas.
Lantus®
Insulin Glargine 100, a long-acting insulin administered subcutaneously and used to treat diabetes mellitus in adults, adolescents and children from the age of 2 years.
Aubagio®
AUBAGIO® is a once-daily oral tablet that is indicated for adult patients with relapsing remitting multiple sclerosis (RRMS)
Lemtrada®
Lemtrada® is a monoclonal antibody produced in mammalian cells (Chinese Hamster Ovary).
Depakine®
Valproate and its valproic acid, sodium valproate, and valproate semisodium forms are medications primarily used to treat epilepsy.
Amaryl®
Glimepiride is an orally active hypoglycaemic substance belonging to the sulfonylurea group. It may be used in non-insulin dependent diabetes mellitus.
Aprovel®
Irbesartan is a potent, orally active, selective angiotensin-II receptor (type AT1) antagonist. It is expected to block all actions of angiotensin-II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin-II used to Effectively control Hypertension to normal Rates.
▼This drug is subject to additional monitoring, the reporting of suspected adverse reactions associated with this drug is a priority.
YOU WILL NOW BE LEAVING THE SITE
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website.
Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.